Researchers at The Wistar Institute's HIV Cure and Viral Diseases Center have successfully identified a new approach using ...

2024年8月，国际知名学术期刊《Cureus》上发表的一项临床病例报告，详细记录了一位61岁晚期肝细胞癌患者在接受联合NK细胞治疗方案（DC疫苗+NK细胞+纳武利尤单抗）后，病情得到显著改善。其中，肝脏储备功能显著改善，肝部肿瘤体积大幅减小，为后续 ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

2025 年 2 月 10 日，中国科学技术大学生命科学与医学部、免疫应答与免疫治疗全国重点实验室王毅课题组在 Cell 子刊 Molecular Therapy 在线发表了题为“ A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy ” 的研究论文 ...

2025 年 2 月 10 日，中国科学技术大学生命科学与医学部、免疫应答与免疫治疗全国重点实验室王毅课题组在 Cell 子刊 Molecular Therapy 在线发表了题为“ A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy ” 的研究论文 肿瘤微环境通过免疫抑制因子失衡 ...

The results from Phase 1 of the Troculeucel Clinical Trial demonstrated stable/improved outcomes in 90% of subjects, with no drug-related adverse ...

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic NK cell therapeutics. NKGen is headquartered in Santa Ana, ...

University of Queensland research using natural killer cells may lead to the first new treatment for a devastating childhood ...